Targeting Mitochondrial Superoxide to Repair Cisplatin Kidney Injury
Official title: Targeting Tubular Mitochondrial Superoxide Dismutation in Cisplatin Renal Repair
Funded at Research Inst Nationwide Children's Hosp · NIH-11399688 · Data updated 2026-11-12
This project tests a treatment that could protect the kidneys of patients receiving cisplatin chemotherapy by boosting mitochondrial antioxidant defense in kidney tubule cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst Nationwide Children's Hosp NIH-funded |
| Lab location | 1 site (Columbus, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $621,810 |
| NIH project number | 5R01DK138101-03 |
| Project ID | NIH-11399688 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients receiving cisplatin chemotherapy who are at risk of kidney injury or CKD, and who could benefit from therapies aimed at protecting renal tubule cells.
✕Less likely to help
Patients without cisplatin exposure or those without kidney injury risk may not benefit from this approach.
What this research studies
Cisplatin can damage kidney tubule cells and lead to chronic kidney disease. The study focuses on a mitochondrially targeted antioxidant, GC4419, to improve energy production and repair in these cells. Researchers will explore how mitochondrial superoxide balance affects cell health, test how increasing dismutation helps kidney cells recover, and look for biomarkers that signal when this therapy works. The work uses animal and human data to connect cellular changes to potential kidney protection in patients.
Why it matters
Potential benefit: If successful, this research could lead to a therapy that reduces cisplatin-related kidney injury and preserves kidney function in patients undergoing treatment.
How similar studies have gone: Prior work shows that mitochondrially targeted antioxidants can protect kidneys in cisplatin-related injury, supporting the potential for benefit.
Where this research is happening
-
Research Inst Nationwide Children's Hosp
Columbus, United States Active
Researchers
- Principal investigator: Zepeda-Orozco, Diana — Research Inst Nationwide Children's Hosp
- Study coordinator: Zepeda-Orozco, Diana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.